TY - JOUR T1 - Influence of HLA class II  DRB1*/DQB1* alleles in phenotypes of Indian patients of sarcoidois JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA703 VL - 58 IS - suppl 65 SP - PA703 AU - Deepak Rosha AU - Mohit Chowdhry AU - Ishan Gupta AU - deepak rosha Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA703.abstract N2 - Sarcoidosis in India differs in many aspects from other ethnic groups. To assess phenotypes related to alleles and to make prognostication, an evaluation of HLA class II alleles DRB1* and DQB1* was done in cases of sarcoidosis in various stages at time of presentation.Fifty sarcoidosis cases of ethnic Indian origin were followed up for atleast 3 years in remission, or 5 years in non remission or death if it occured during the study period. There were 25 females and 25 males in the study. A matched control group of hundred healthy kidney donors were included for comparison. Phenotype grouping was done so that radiological Stage I was in Group I and Group II included all other stages. There were 15 patients in Group I and 35 in Group II.It was found that HLA-DRB1*14 indicated poor prognosis(p<.05) as did HLA-DRB1*07(Odds Ratio 2.07). This was consistent with other studies. But in variance with other studies it was noted that  HLA-DRB1*15  indicated a good prognosis (p<.05). HLA-DRB1*11 gave a varible result on correlating haploidentical alleles present in phenotypes. HLA-DQB1*02 and DQB1*06 were associated with uveitis in Group I where as it has been shown that uveitis in Japan and Holland has been associated with HLA-DRB1*04. Lofgrens syndrome (LS) was not seen in our series and the allele HLA-DRB1*03 was rarely seen.In conclusion the HLA class II alleles associated with Indian phenotypes of sarcoidosis are  different from other ethnic groups. Genetic evaluation is strongly recommended for prognostication and follow up of these patients.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA703.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -